<DOC>
	<DOC>NCT01888198</DOC>
	<brief_summary>The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection</brief_summary>
	<brief_title>Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Retrospective enrollment: Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal mass. Prospective enrollment: Patients scheduled to undergo, rather than having undergone, percutaneous, open or laparoscopic energy ablation of a renal mass. Patients not having undergone, or considered candidates for percutaneous, open or laparoscopic energy ablation of a renal mass NonEnglish speaking patients Patients under the age of 18.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ablation</keyword>
	<keyword>quality of Life (QOL)</keyword>
	<keyword>kidney</keyword>
	<keyword>registry</keyword>
	<keyword>Ablation of Renal Masses Outcomes Registry (ARMOR)</keyword>
	<keyword>13-116</keyword>
</DOC>